Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation

Lina Gao, Jacob Schwartzman, Angela Gibbs, Robert Lisac, Richard Kleinschmidt, Beth Wilmot, Daniel Bottomly, Ilsa Coleman, Peter Nelson, Shannon McWeeney, Joshi Alumkal

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus. However, some patients do not benefit, and those tumors that do initially respond to ADT eventually progress. One recently described mechanism of such an effect is growth and survival-promoting effects of the AR that are exerted independently of the AR ligands, testosterone and dihydrotestosterone. However, specific ligand-independent AR target genes that account for this effect were not well characterized. We show here that c-Myc, which is a key mediator of ligand-independent prostate cancer growth, is a key ligand-independent AR target gene. Using microarray analysis, we found that c-Myc and AR expression levels strongly correlated with each other in tumors from patients with castration-resistant prostate cancer (CRPC) progressing despite ADT. We confirmed that AR directly regulates c-Myc transcription in a ligand-independent manner, that AR and c-Myc suppression reduces ligand-independent prostate cancer cell growth, and that ectopic expression of c-Myc attenuates the anti-growth effects of AR suppression. Importantly, treatment with the bromodomain inhibitor JQ1 suppressed c-Myc function and suppressed ligand-independent prostate cancer cell survival. Our results define a new link between two critical proteins in prostate cancer - AR and c-Myc - and demonstrate the potential of AR and c-Myc-directed therapies to improve prostate cancer control.

Original languageEnglish (US)
Article numbere63563
JournalPLoS One
Volume8
Issue number5
DOIs
StatePublished - May 21 2013

Fingerprint

Androgen Receptors
prostatic neoplasms
Prostatic Neoplasms
Up-Regulation
Ligands
therapeutics
androgens
Androgens
Growth
Therapeutics
Tumors
ligands
androgen receptors
Genes
neoplasms
Dihydrotestosterone
Castration
Cell growth
Transcription
castration

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation. / Gao, Lina; Schwartzman, Jacob; Gibbs, Angela; Lisac, Robert; Kleinschmidt, Richard; Wilmot, Beth; Bottomly, Daniel; Coleman, Ilsa; Nelson, Peter; McWeeney, Shannon; Alumkal, Joshi.

In: PLoS One, Vol. 8, No. 5, e63563, 21.05.2013.

Research output: Contribution to journalArticle

Gao, L, Schwartzman, J, Gibbs, A, Lisac, R, Kleinschmidt, R, Wilmot, B, Bottomly, D, Coleman, I, Nelson, P, McWeeney, S & Alumkal, J 2013, 'Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation', PLoS One, vol. 8, no. 5, e63563. https://doi.org/10.1371/journal.pone.0063563
Gao, Lina ; Schwartzman, Jacob ; Gibbs, Angela ; Lisac, Robert ; Kleinschmidt, Richard ; Wilmot, Beth ; Bottomly, Daniel ; Coleman, Ilsa ; Nelson, Peter ; McWeeney, Shannon ; Alumkal, Joshi. / Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation. In: PLoS One. 2013 ; Vol. 8, No. 5.
@article{f75aa4e82ee546de9b0ab9c1d298cd8e,
title = "Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation",
abstract = "The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus. However, some patients do not benefit, and those tumors that do initially respond to ADT eventually progress. One recently described mechanism of such an effect is growth and survival-promoting effects of the AR that are exerted independently of the AR ligands, testosterone and dihydrotestosterone. However, specific ligand-independent AR target genes that account for this effect were not well characterized. We show here that c-Myc, which is a key mediator of ligand-independent prostate cancer growth, is a key ligand-independent AR target gene. Using microarray analysis, we found that c-Myc and AR expression levels strongly correlated with each other in tumors from patients with castration-resistant prostate cancer (CRPC) progressing despite ADT. We confirmed that AR directly regulates c-Myc transcription in a ligand-independent manner, that AR and c-Myc suppression reduces ligand-independent prostate cancer cell growth, and that ectopic expression of c-Myc attenuates the anti-growth effects of AR suppression. Importantly, treatment with the bromodomain inhibitor JQ1 suppressed c-Myc function and suppressed ligand-independent prostate cancer cell survival. Our results define a new link between two critical proteins in prostate cancer - AR and c-Myc - and demonstrate the potential of AR and c-Myc-directed therapies to improve prostate cancer control.",
author = "Lina Gao and Jacob Schwartzman and Angela Gibbs and Robert Lisac and Richard Kleinschmidt and Beth Wilmot and Daniel Bottomly and Ilsa Coleman and Peter Nelson and Shannon McWeeney and Joshi Alumkal",
year = "2013",
month = "5",
day = "21",
doi = "10.1371/journal.pone.0063563",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation

AU - Gao, Lina

AU - Schwartzman, Jacob

AU - Gibbs, Angela

AU - Lisac, Robert

AU - Kleinschmidt, Richard

AU - Wilmot, Beth

AU - Bottomly, Daniel

AU - Coleman, Ilsa

AU - Nelson, Peter

AU - McWeeney, Shannon

AU - Alumkal, Joshi

PY - 2013/5/21

Y1 - 2013/5/21

N2 - The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus. However, some patients do not benefit, and those tumors that do initially respond to ADT eventually progress. One recently described mechanism of such an effect is growth and survival-promoting effects of the AR that are exerted independently of the AR ligands, testosterone and dihydrotestosterone. However, specific ligand-independent AR target genes that account for this effect were not well characterized. We show here that c-Myc, which is a key mediator of ligand-independent prostate cancer growth, is a key ligand-independent AR target gene. Using microarray analysis, we found that c-Myc and AR expression levels strongly correlated with each other in tumors from patients with castration-resistant prostate cancer (CRPC) progressing despite ADT. We confirmed that AR directly regulates c-Myc transcription in a ligand-independent manner, that AR and c-Myc suppression reduces ligand-independent prostate cancer cell growth, and that ectopic expression of c-Myc attenuates the anti-growth effects of AR suppression. Importantly, treatment with the bromodomain inhibitor JQ1 suppressed c-Myc function and suppressed ligand-independent prostate cancer cell survival. Our results define a new link between two critical proteins in prostate cancer - AR and c-Myc - and demonstrate the potential of AR and c-Myc-directed therapies to improve prostate cancer control.

AB - The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus. However, some patients do not benefit, and those tumors that do initially respond to ADT eventually progress. One recently described mechanism of such an effect is growth and survival-promoting effects of the AR that are exerted independently of the AR ligands, testosterone and dihydrotestosterone. However, specific ligand-independent AR target genes that account for this effect were not well characterized. We show here that c-Myc, which is a key mediator of ligand-independent prostate cancer growth, is a key ligand-independent AR target gene. Using microarray analysis, we found that c-Myc and AR expression levels strongly correlated with each other in tumors from patients with castration-resistant prostate cancer (CRPC) progressing despite ADT. We confirmed that AR directly regulates c-Myc transcription in a ligand-independent manner, that AR and c-Myc suppression reduces ligand-independent prostate cancer cell growth, and that ectopic expression of c-Myc attenuates the anti-growth effects of AR suppression. Importantly, treatment with the bromodomain inhibitor JQ1 suppressed c-Myc function and suppressed ligand-independent prostate cancer cell survival. Our results define a new link between two critical proteins in prostate cancer - AR and c-Myc - and demonstrate the potential of AR and c-Myc-directed therapies to improve prostate cancer control.

UR - http://www.scopus.com/inward/record.url?scp=84877934286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877934286&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0063563

DO - 10.1371/journal.pone.0063563

M3 - Article

C2 - 23704919

AN - SCOPUS:84877934286

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e63563

ER -